A virtual library of 30 isoniazid-based Schiff base derivatives was computationally screened, and the top-ranked compound SLB ...

Tuberculosis (TB) is the world's biggest infectious disease killer, with multidrug-resistant TB (MDR-TB) posing a particular threat to global health. A study led by the Swiss Tropical and Public ...

The next major advancement in TB might not be a new drug, but a better understanding of how and why resistance to medicines ...

Tuberculosis (TB) is the world's deadliest infectious disease—and one of the hardest to cure. Standard treatment requires a cocktail of multiple drugs over at least six months, and one in five ...

AN2 Therapeutics has received an extension of funding from the Gates Foundation to support its ongoing tuberculosis research ...

Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, ...

A new study uncovers vulnerabilities in drug-resistant TB, offering hope for improved treatments. Rutgers Health research has uncovered why a relatively new antibiotic for tuberculosis (TB) works ...

Researchers have discovered that over-the-counter drugs commonly used to treat heartburn could shorten the treatment of tuberculosis (TB). These drugs could also reduce the chances of the bacteria ...

Could a common over-the-counter anti-inflammatory drug become a new weapon against drug-resistant tuberculosis? Early findings suggest immune benefits, but larger trials are needed to determine ...

Rutgers Health research has uncovered why a relatively new antibiotic for tuberculosis (TB) works against multidrug-resistant strains, potentially inspiring improved treatments and drug development ...